AxImmune
AxImmune, Inc. is a clinical stage immuno-oncology company developing innovative therapies in-licensed from Colorado State University and Axon Connected, LLC. Their lead candidate, Ax-101, is a potent immuno-modulary agent that works synergistically with immune checkpoint inhibitors to improve cancer treatment outcomes. The company aims to expand the range of cancers treatable with immune checkpoint drugs and increase the number of patients achieving complete recovery and immunity against recurrence.
Industries
Nr. of Employees
small (1-50)
AxImmune
Fort Collins, Colorado, United States, North America
Patents
Products
Small-molecule immuno-oncology therapeutic (clinical candidate)
A small-molecule immuno-modulatory drug candidate with demonstrated single-agent anti-tumor activity in preclinical and prior human studies; shown in animal models to act synergistically with immune checkpoint inhibitors and to improve tumor growth inhibition and cure rates in combination settings.
Small-molecule immuno-oncology therapeutic (clinical candidate)
A small-molecule immuno-modulatory drug candidate with demonstrated single-agent anti-tumor activity in preclinical and prior human studies; shown in animal models to act synergistically with immune checkpoint inhibitors and to improve tumor growth inhibition and cure rates in combination settings.
Services
Preparation and submission of IND regulatory filings and sponsor-led planning to initiate multi-site early-phase clinical trials.
Coordination and oversight of preclinical in vivo studies at academic and independent laboratories to evaluate efficacy and combination effects with immune checkpoint inhibitors.
Preparation and submission of IND regulatory filings and sponsor-led planning to initiate multi-site early-phase clinical trials.
Coordination and oversight of preclinical in vivo studies at academic and independent laboratories to evaluate efficacy and combination effects with immune checkpoint inhibitors.
Expertise Areas
- Immuno-oncology drug development
- Preclinical efficacy testing and animal models
- Translational oncology research
- Early-phase clinical development and trial management
Key Technologies
- Small-molecule therapeutics
- Combination therapy with immune checkpoint inhibitors (PD-1/CTLA-4 pathways)
- In vivo animal efficacy models
- Translational research methods